

# Contents

<b>1</b>	<b>Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens</b> . . . . .	1
	Introduction . . . . .	1
	Testing Methods for Estrogen . . . . .	2
	Structure-Activity Relationships of Estrogens . . . . .	3
	Estrogen Action . . . . .	6
	Nonsteroidal Antiestrogens . . . . .	7
	Structure-Activity Relationships in the Rat . . . . .	7
	Substituted Triphenylethylenes . . . . .	7
	Bicyclic Antiestrogens . . . . .	9
	The Molecular Modulation of the Estrogen Receptor by Nonsteroidal Antiestrogens . . . . .	12
	Effect of Antiestrogens in Different Species . . . . .	16
	Mouse . . . . .	17
	Rat . . . . .	18
	Chick . . . . .	20
	Conclusion . . . . .	20
	References . . . . .	22
<b>2</b>	<b>Tamoxifen Goes Forward Alone</b> . . . . .	31
	Introduction . . . . .	31
	ICI 46,474: The Early Years . . . . .	33
	ICI 46,474 to Tamoxifen . . . . .	37
	Patenting Problems . . . . .	39
	Conclusion . . . . .	40
	References . . . . .	42
<b>3</b>	<b>Metabolites of Tamoxifen as the Basis of Drug Development</b> . . . . .	47
	Introduction . . . . .	47
	Basic Mechanisms of Tamoxifen Metabolism . . . . .	48
	Metabolic Mimicry . . . . .	52
	Tamoxifen Metabolism Today . . . . .	55

Clinical Correlations . . . . .	57
References . . . . .	60
<b>4 Adjuvant Therapy: The Breakthrough . . . . .</b>	<b>69</b>
Introduction . . . . .	69
Adjuvant Therapy with Tamoxifen . . . . .	70
Studies in Premenopausal Women . . . . .	73
Overview of Clinical Trials . . . . .	74
Arrival of Aromatase Inhibitors as Adjuvant Therapy . . . . .	76
Increasing Survivorship Following 5 Years of Adjuvant Tamoxifen . . . . .	77
References . . . . .	80
<b>5 The Wisconsin Story in the 1980s: Discovery of Target   Site-Specific Estrogen Action . . . . .</b>	<b>85</b>
Introduction . . . . .	85
Laboratory Studies on the Target Site-Specific Pharmacology of “Nonsteroidal Antiestrogens” . . . . .	86
The Wisconsin Tamoxifen Study . . . . .	89
Translational Research . . . . .	90
References . . . . .	96
<b>6 Carcinogenesis and Tamoxifen . . . . .</b>	<b>101</b>
Introduction . . . . .	101
Tamoxifen and the Endometrial Carcinoma . . . . .	102
Deaths from Endometrial Carcinoma . . . . .	103
Tamoxifen and the Stage of Endometrial Carcinoma . . . . .	104
Incidence of Endometrial Cancer with Tamoxifen . . . . .	105
Tamoxifen and Rat Liver Carcinogenesis . . . . .	107
Tamoxifen and DNA Adduct Formation . . . . .	108
Doses of Tamoxifen in Animals and Man . . . . .	109
Testing at Comparable Therapeutic Levels . . . . .	110
Conclusion . . . . .	111
References . . . . .	113
<b>7 Chemoprevention: Cinderella Waiting for the Ball . . . . .</b>	<b>115</b>
Introduction . . . . .	115
The Link Between Estrogen and Breast Cancer . . . . .	116
Prevention of Mammary Cancer in Rodents . . . . .	117
Tamoxifen: The First SERM for the Prevention of Breast Cancer in High-Risk Populations . . . . .	119
Royal Marsden Study . . . . .	120
NSABP/NCI P-1 Study . . . . .	122
Italian Study . . . . .	125
The International Breast Cancer Intervention Study (IBIS-I) . . . . .	126
Follow-Up of Chemoprevention Studies with Tamoxifen . . . . .	127

Two Approaches to the Chemoprevention of Breast Cancer . . . . .	127
Raloxifene: Abandoned and Resurrected . . . . .	128
Conclusion . . . . .	131
References . . . . .	131
<b>8 Tamoxifen and Raloxifene Head to Head: The STAR Trial . . . . .</b>	<b>135</b>
References . . . . .	141
<b>9 Acquired Resistance to Tamoxifen: Back to the Beginning . . . . .</b>	<b>143</b>
Introduction . . . . .	143
The MCF-7 Breast Cancer Cell Line . . . . .	144
Tamoxifen Metabolism Hypothesis . . . . .	145
Growth Factor-Driven Acquired and Intrinsic Resistance . . . . .	146
An Evolving Model of Acquired Resistance to SERMs and Aromatase Inhibitors . . . . .	147
Back to the Beginning . . . . .	149
Mechanisms of Estrogen-Induced Apoptosis . . . . .	150
A New Classification of Estrogens . . . . .	152
Final Thoughts on Four Decades of Discovery to Advance the Value of the ER Target in Breast Cancer . . . . .	153
References . . . . .	157
<b>10 The Legacy of Tamoxifen . . . . .</b>	<b>165</b>
Introduction . . . . .	165
Pure Antiestrogens . . . . .	166
SERM Successes . . . . .	168
Lasofloxifene (CP-336156, Fablyn) . . . . .	169
Bazedoxifene (TSE-424, WAY-140424) . . . . .	170
Ospemifene (FC-1271a) . . . . .	170
Refining the SERM Concept Further . . . . .	171
References . . . . .	174
<b>Appendix A: Four Decades of Discovery in Breast Cancer Research and Treatment: An Interview with V. Craig Jordan . . . . .</b>	<b>179</b>
<b>Appendix B: Selected Awards That Recognize the Contribution of Tamoxifen and Raloxifene to Medicine . . . . .</b>	<b>197</b>